Advertising and Promotional Material Review for Therapeutic Goods in Australia

As leading experts in TGA advertising & compliance, Adjutor can conduct a thorough Advertising and Promotional Material Review for your Therapeutic Goods.

Navigating advertising compliance for therapeutic goods in Australia can feel like walking a tightrope. With multiple advertising laws enforced by different regulators, businesses must tread carefully to avoid penalties or legal complications. Whether you’re marketing to the public or healthcare professionals, understanding the rules is critical for staying compliant while reaching your target audience effectively.

Advertising and Promotional Material Review Services

At Adjutor, we specialise in ensuring your advertising and promotional materials meet all legislative requirements and industry standards.

Advertising for therapeutic goods goes beyond traditional ads. The Therapeutic Goods Administration (TGA) defines it as any statement, pictorial representation or design that promotes the use or supply of the product.

This includes:

  • Articles published in journals, magazines and newspapers
  • Posters and notices, photographs
  • Broadcast media such as films, video, electronic transmissions
  • Online material, including websites and social media.
  • Sales materials, such as catalogues, inserts, leaflets, and booklets that include specific product claims, even if not provided with the product

Essentially, if it promotes your product, it’s likely considered advertising – and must comply with stringent regulatory standards.

The Therapeutic Goods Advertising Code (the Code), underpinned by the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 governs the advertising of therapeutic goods in Australia.

The Code outlines minimum requirements for advertising therapeutic goods to consumers in Australia, requiring advertisements to:

Additionally, various industry organisations like Medicines Australia, Medical Technology Association of Australia and Consumer Healthcare Products Australia enforce codes of practice for advertising and promotional materials directed to healthcare professionals. These supplementary requirements can add another layer of complexity for businesses to navigate.

In November 2018, The Therapeutic Goods Administration (TGA) published new guidance on advertising therapeutic goods in Australia, which included websites and social media. This came into force on 1st Jan 2019.

TGA recently updated its guidance on advertising cosmetic injectables to ensure consistency across all industries handling therapeutic goods. In the past, generic, non-product-specific words such as ‘wrinkle-reducing injections’ were permitted only when promoting services if they avoided product references, such as ‘Botox’ or ‘botulinum toxin’.

However, TGA recently discovered that clinics and other health services indirectly advertised prescription drugs, using terms like “weight loss injections”, “medicinal cannabis” or “nicotine vaping products”. This prompted a reinterpretation: such references, even when generic, are now considered promotional statements for therapeutic goods, which is illegal.

Effective 2024, terms such as “wrinkle reducing injections” are not permitted if those terms suggest to a reasonable consumer that prescription drugs are being advertised. The revised guidance on advertising cosmetic injectables is available on the TGA website.

Businesses in the cosmetic industry must adjust their marketing strategies accordingly to comply with these stricter rules.

As leading experts in TGA advertising & compliance, Adjutor can conduct a thorough Advertising and Promotional Material Review for your Therapeutic Goods.

Advertising therapeutic goods in Australia is complex—but you don’t have to face it alone. At Adjutor, we specialise in ensuring your advertising and promotional materials meet all legislative requirements and industry standards.

Our team of regulatory experts is here to help you:

  • Conduct comprehensive reviews of your advertising and promotional content
  • Provide practical, actionable advice to achieve compliance
  • Navigate evolving regulations and industry-specific requirements

Contact our team of experts to learn how we can help your business succeed.

More recent articles

  • Pharmaceutical Quality Assurance Australia and NZ

    Pharmaceutical Quality Assurance Australia and NZ

    The Critical Importance of Quality Assurance (QA) in Drug Development, Clinical Trials, and Importation into Australia and New Zealand. Why Pharmaceutical Quality Assurance Matters Maintaining high-quality standards throughout every stage of drug development, including nonclinical research, clinical trials, manufacturing, supply chain, and importation, is essential for protecting patient safety, ensuring product efficacy, and fulfilling regulatory…

  • Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    The Access Consortium is a coalition of like-minded regulatory authorities working together to promote greater regulatory collaboration and alignment of regulatory requirements. Learn how the ACCESS Consortium can streamline medicine approvals in Australia and partner countries, accelerating access to new therapies. Australia as an Early Entry Market for Medicines Australia is an increasingly attractive early…

  • Life Sciences Expansion Strategies Greater Bay Area – China

    Life Sciences Expansion Strategies Greater Bay Area – China

    China’s Greater Bay Area (GBA) initiative aims to create a single, integrated economic zone, fostering innovation, connectivity, and environmental sustainability. We explore how the Greater Bay Area (GBA) is transforming life sciences and medical device access in China, with regulatory benefits and streamlined market entry opportunities. What is the Greater Bay Area (GBA)? The Greater…